Genvor Inc

Genvor, Inc. (OTCQB: GNVR) is a biotechnology company harnessing artificial intelligence to generate novel peptides that deliver high-performance solutions across agriculture and human health. The company's proprietary BioCypher platform uses AI-driven computational methods to design and optimize biological active compounds — specifically peptides, which are short chains of amino acids that can perform highly targeted biological functions in living organisms. By combining computational biology with machine learning capabilities, BioCypher enables Genvor to accelerate the discovery and development of novel peptide candidates that would take far longer to identify and optimize through traditional laboratory screening approaches.<br><br>In the agriculture sector, Genvor is developing biological actives for crop protection and plant health — a market that has seen growing demand for biopesticides and biostimulants as growers and regulatory agencies seek alternatives to synthetic chemical crop protection products. Peptide-based crop protection compounds can offer advantages in terms of environmental degradation profiles, residue levels, and compatibility with integrated pest management programs. On the human health side, Genvor is developing consumer-focused peptide solutions targeting recovery, athletic performance, anti-aging, and daily wellness — categories where peptide ingredients have become increasingly prominent in premium supplement and functional product formulations.<br><br>Genvor, Inc. was incorporated in Nevada and its common stock trades on the OTCQB Venture Market under the ticker symbol GNVR, reflecting the company's status as a reporting company filing periodic reports with the Securities and Exchange Commission. In May 2026, the company appointed Donald Kalkofen as Chief Financial Officer, a seasoned biotechnology executive with more than twenty years of public company finance leadership and initial public offering experience. As the convergence of artificial intelligence and bioscience continues to reshape drug discovery and agricultural biotechnology, Genvor's AI-driven peptide platform positions the company to develop a diversified pipeline of proprietary biological actives serving both plant science and human health markets.